Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Single Dose Study of LY2605541 in Participants With Liver Impairment

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01751399
First received: December 14, 2012
Last updated: January 17, 2014
Last verified: January 2014
  Purpose

The primary purpose of this study is to help answer the following research questions:

  • To evaluate how much of the study drug (LY2605541) is in the blood of participants with varying degrees of liver impairment compared to those with normal liver function
  • To assess the safety of LY2605541 and any side effects that might be associated with it

Condition Intervention Phase
Healthy Volunteers
Hepatic Insufficiency
Diabetes Mellitus, Type 2
Drug: LY2605541
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Single Dose Pharmacokinetic Study of LY2605541 in Subjects With Hepatic Impairment

Further study details as provided by Eli Lilly and Company:

Primary Outcome Measures:
  • Pharmacokinetics: Area Under the Concentration Time Curve from Zero to Infinity (AUC[0-∞]) of LY2605541 [ Time Frame: Predose up to 216 hours post dose ] [ Designated as safety issue: No ]
  • Pharmacokinetics: Maximum Concentration (Cmax) of LY2605541 [ Time Frame: Predose up to 216 hours post dose ] [ Designated as safety issue: No ]

Estimated Enrollment: 60
Study Start Date: December 2012
Study Completion Date: September 2013
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LY2605541-Normal Hepatic Function
Participants will receive a single subcutaneous (SC) dose of 0.075 milligram per kilogram (mg/kg) LY2605541
Drug: LY2605541
Administered once as single SC dose
Experimental: LY2605541-Mild Hepatic Impairment
Participants will receive a single SC dose of 0.075 mg/kg LY2605541
Drug: LY2605541
Administered once as single SC dose
Experimental: LY2605541-Moderate Hepatic Impairment
Participants will receive a single SC dose of 0.075 mg/kg LY2605541
Drug: LY2605541
Administered once as single SC dose
Experimental: LY2605541-Severe Hepatic Impairment
Participants will receive a single SC dose of 0.075 mg/kg LY2605541
Drug: LY2605541
Administered once as single SC dose

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

All Participants (including those with type 2 diabetes mellitus who are controlled by diet)

  • Male participants agree to use a reliable method of birth control during the study
  • Female participants of child-bearing potential (not surgically sterilized between menarche and menopause) must have a negative pregnancy test at the time of enrollment and must be using a reliable method of birth control
  • Women not of child-bearing potential due to surgical sterilization (at least 6 weeks after surgical bilateral oophorectomy with or without hysterectomy or at least 6 weeks after tubal ligation) confirmed by medical history, or menopause.
  • Menopausal women include women with either spontaneous amenorrhea for at least 12 months or spontaneous amenorrhea for 6 to 12 months and a follicle-stimulating hormone (FSH) level greater than 40 milli international units per milliliter (mIU/mL)
  • Have a body mass index (BMI) of 18.5 to 40 kilogram per square meter (kg/m^2)
  • Have normal sitting blood pressure and heart rate compatible with their disease state
  • Have venous access sufficient to allow blood sampling
  • Have given written informed consent approved by Lilly and the Ethical Review Board (ERB) governing the site

Participants with Normal Hepatic Function

  • Overtly healthy males or females with normal hepatic function
  • Have clinical laboratory test results within normal reference range for the investigator site, or results with minor deviations not considered to be clinically significant by the investigator

Participants with Hepatic Impairment

- Have stable liver impairment with no sign of recent deterioration (alcoholic, posthepatitis, biliary cirrhosis, cryptogenic) classified as Child-Pugh class A, B, or C who are considered by the investigator as acceptable for participation in the study

Exclusion Criteria:

All Participants (including those with type 2 diabetes mellitus)

  • Are currently enrolled in, have completed or discontinued within the last 30 days from a clinical trial involving an investigational product, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
  • Have an acute infection with fever or infectious disease or febrile illness within 3 days prior to administration of the study medication
  • Have known allergies or significant hypersensitivity to LY2605541, its excipients, or related compounds, or history of relevant allergic reactions of any origin
  • Are persons who have previously completed or withdrawn from this study or any other study investigating LY2605541, and have previously received the investigational product
  • Have Type 1 Diabetes Mellitus (T1DM) or have Type 2 Diabetes Mellitus (T2DM) and are receiving anti-diabetic medication
  • Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study
  • Regularly use known drugs of abuse and/or show positive findings on urinary drug screening
  • Show evidence of human immunodeficiency virus infection and/or positive human immunodeficiency virus (HIV) antibodies
  • Have donated blood of more than 500 milliliters (mL) within the last month
  • Have had a liver transplant or have taken immunosuppressants following any organ transplant
  • Have shown signs of variceal bleeding during the last 2 weeks prior to screening
  • Show evidence of irritable bowel syndrome, chronic diarrhea, other symptomatic digestive problems or a known history of repeated chronic stool positive for occult blood, or be considered by the investigator to be at greater risk of acute or chronic pancreatitis
  • Have an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week (females), or are unwilling to stop alcohol consumption for the duration of the study
  • Are on total parenteral nutrition
  • Take anticoagulants for therapeutic use, other than low dose acetylsalicyclic acid
  • Are excessive consumers of xanthines

Participants with Normal Hepatic Function

  • Have any medically significant history of neurologic disease, cancer, or cardiac, respiratory, metabolic, hepatic, renal, gastrointestinal (except appendectomy and cholecystectomy), dermatological, venereal, hematological disorder or disease
  • Have creatinine clearance (CrCl) less than 80 milliliters per minute (mL/min)
  • Show evidence of significant active neuropsychiatric disease in the opinion of the investigator
  • Show evidence of hepatitis B and/or positive hepatitis B surface antigen
  • Show evidence of hepatitis C and/or positive hepatitis C antibody

Participants with Hepatic Impairment

  • Show evidence of any significant active disease other than that responsible for or associated with mild, moderate, or severe hepatic impairment
  • Show evidence of hepatorenal syndrome as shown by creatinine clearance (CrCl) <50 milliliter per minute (mL/min) calculated using the Cockcroft-Gault equation
  • Have shown signs of spontaneous bacterial peritonitis within 6 months prior to enrollment into the study
  • Have severe hyponatremia (sodium <120 millimole per liter [mmol/L])
  • Show signs of hepatocellular carcinoma
  • Have a portal shunt
  • Show, in the opinion of the investigator, evidence of significant active neuropsychiatric disease other than grade 1 hepatic encephalopathy
  • Have hemoglobin concentrations <9.0 grams per deciliter (g/dL)
  • Have a platelet count of <30 x 10^9 cells per liter (cells/L), unless, after consultation with the sponsor, they are considered as acceptable for participation in the study
  • Have total serum bilirubin concentrations >15 milligrams per deciliter (mg/dL) (>257 micromoles per liter (μmol/L))
  • Take medications known to interfere with hepatic metabolism (for example barbiturates, phenothiayines) or known to alter other major organ systems
  • Show signs of acute cholestasis or acute cholecystitis
  • Have severe ascites
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01751399

Locations
Germany
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Munich, Germany, 81241
Hungary
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Balatonfured, Hungary, 8230
Sponsors and Collaborators
Eli Lilly and Company
Investigators
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
  More Information

No publications provided

Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT01751399     History of Changes
Other Study ID Numbers: 14205, I2R-MC-BIDA
Study First Received: December 14, 2012
Last Updated: January 17, 2014
Health Authority: United States: Food and Drug Administration
Germany: Federal Institute for Drugs and Medical Devices
Hungary: National Institute of Pharmacy

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Hepatic Insufficiency
Digestive System Diseases
Endocrine System Diseases
Glucose Metabolism Disorders
Liver Diseases
Metabolic Diseases

ClinicalTrials.gov processed this record on November 20, 2014